Market Overview:
The global transforming growth factor beta 1 (TGF-β1) market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market is segmented by type, application, and region. By type, the market is divided into pirfenidone, galunisertib, and others. By application, the market is classified into idiopathic pulmonary fibrosis (IPF), cancer, and others. Geographically, the market is analyzed across North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific(China Japan India South Korea Australia New Zealand), and Middle East & Africa(GCC Countries Turkey Nigeria South Africa). The factors that are driving the growth of the global TGF-β1market include increasing prevalence of chronic diseases such as cancer and IPF; rising demand for effective therapies for treatment of chronic diseases; growing awareness about TGF-β1 therapy among physicians; increasing number of clinical trials for TGF-β1 therapy;and rising investment in research.
Product Definition:
transforming growth factor beta 1: a protein that is produced by cells.
Pirfenidone:
pirfenidone is a novel oral anti-inflammatory drug developed by the pharmaceutical company Eisai. It is an analog of etanercept, which was previously approved as a TNF inhibitor but later found to have higher incidence of side effects such as cytokine storm and fatalities compared to other drugs in the same class.
pirfenidone has been shown to be more effective than etanercept in reducing signs.
Galunisertib:
Galunisertib (Ranibizumab) is a humanized monoclonal antibody designed for the treatment of patients with relapsed or refractory large B-cell lymphoma and multiple myeloma. Galunisertib is an investigational drug and has not been approved by the U.S. FDA as of now.
Application Insights:
The other applications segment includes rheumatoid arthritis, osteoarthritis, and others. The global market for TGF beta products in this segment is expected to witness a CAGR of XX% from 2018 to 2030 owing to the growing geriatric population base and rising prevalence of chronic diseases such as cancer & autoimmune disorders that require treatment with growth factors.
In 2017, the oncology segment dominated the overall industry revenue generating capacity with a share of over 40%. This is attributed to increasing incidence rates for various types of cancers across the globe coupled with an increase in approvals for new drugs containing TGF-beta1 activity. For instance; In April 2017 Pfizer Inc., a U.S.
Regional Analysis:
North America was the largest regional market in 2017 owing to the presence of key manufacturers and a large number of clinical trials. The region is expected to maintain its dominance over the forecast period due to an increase in R&D activities, high healthcare expenditure, and rising prevalence of cancer and other diseases. In addition, increasing government funding for research activities is also anticipated to propel growth during the forecast period.
Asia Pacific is projected to be one of fastest-growing regions during the same period owing with growing medical tourism industry supported by low treatment cost in countries such as India & China & Malaysia etc., which has encouraged people from all over world for undergoing various treatments such as stem cell therapy or gene therapy at affordable costs thereby boosting product demand. Moreover, Japan’s approval for commercialization will further boost regional growth during future years (IPF 2018). However, recently China has been witnessing a decline due change in regulations thus affecting its revenue share (Galunisertib 2018).
Growth Factors:
- Increasing prevalence of chronic diseases: The increasing prevalence of chronic diseases is one of the key growth drivers for the transforming growth factor beta 1 market. According to a study by the World Health Organization (WHO), it is estimated that around 36 million people die every year due to non-communicable diseases, which account for 63% of all global deaths. This number is expected to increase to over 53 million by 2030. The growing incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is propelling the demand for transforming growth factor beta 1 products and services worldwide.
- Rising geriatric population: Another major driver for the transforming growth factor beta 1 market is the rising geriatric population across the globe. With advances in medical technology and healthcare facilities, people are living longer than ever before. This has resulted in an increase in the number of elderly people who are susceptible to various age-related health conditions such as arthritis, Alzheimer’s disease, and osteoporosis. As a result, there is a growing demand for therapies that can help improve these conditions, which is driving demand for transforming growth factor beta 1 products and services globally
Scope Of The Report
Report Attributes
Report Details
Report Title
Transforming Growth Factor Beta 1 Market Research Report
By Type
Pirfenidone, Galunisertib, Others
By Application
IPF, Cancer, Others
By Companies
Roche, Shionogi Ltd, Acceleron Pharma Inc, Genzyme Corp, Isarna Therapeutics GmbH, Scholar Rock, Sirnaomics Inc, Eli Lilly and Co, Formation Biologics Inc, Novartis AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Transforming Growth Factor Beta 1 Market Report Segments:
The global Transforming Growth Factor Beta 1 market is segmented on the basis of:
Types
Pirfenidone, Galunisertib, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
IPF, Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Shionogi Ltd
- Acceleron Pharma Inc
- Genzyme Corp
- Isarna Therapeutics GmbH
- Scholar Rock
- Sirnaomics Inc
- Eli Lilly and Co
- Formation Biologics Inc
- Novartis AG
Highlights of The Transforming Growth Factor Beta 1 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Pirfenidone
- Galunisertib
- Others
- By Application:
- IPF
- Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Transforming Growth Factor Beta 1 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Transforming growth factor beta 1 (TGF-beta1) is a protein that helps the body to grow and repair tissues. It is also involved in the development of cancer.
Some of the major companies in the transforming growth factor beta 1 market are Roche, Shionogi Ltd, Acceleron Pharma Inc, Genzyme Corp, Isarna Therapeutics GmbH, Scholar Rock, Sirnaomics Inc, Eli Lilly and Co, Formation Biologics Inc, Novartis AG.
The transforming growth factor beta 1 market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Transforming Growth Factor Beta 1 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Transforming Growth Factor Beta 1 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Transforming Growth Factor Beta 1 Market - Supply Chain
4.5. Global Transforming Growth Factor Beta 1 Market Forecast
4.5.1. Transforming Growth Factor Beta 1 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Transforming Growth Factor Beta 1 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Transforming Growth Factor Beta 1 Market Absolute $ Opportunity
5. Global Transforming Growth Factor Beta 1 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Type
5.3.1. Pirfenidone
5.3.2. Galunisertib
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Transforming Growth Factor Beta 1 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Application
6.3.1. IPF
6.3.2. Cancer
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Transforming Growth Factor Beta 1 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Transforming Growth Factor Beta 1 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Transforming Growth Factor Beta 1 Demand Share Forecast, 2019-2026
9. North America Transforming Growth Factor Beta 1 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Application
9.4.1. IPF
9.4.2. Cancer
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Type
9.7.1. Pirfenidone
9.7.2. Galunisertib
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Transforming Growth Factor Beta 1 Demand Share Forecast, 2019-2026
10. Latin America Transforming Growth Factor Beta 1 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Application
10.4.1. IPF
10.4.2. Cancer
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Type
10.7.1. Pirfenidone
10.7.2. Galunisertib
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Transforming Growth Factor Beta 1 Demand Share Forecast, 2019-2026
11. Europe Transforming Growth Factor Beta 1 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Application
11.4.1. IPF
11.4.2. Cancer
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Type
11.7.1. Pirfenidone
11.7.2. Galunisertib
11.7.3. Others
11.8. Basis Poit Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Transforming Growth Factor Beta 1 Demand Share, 2019-2026
12. Asia Pacific Transforming Growth Factor Beta 1 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Application
12.4.1. IPF
12.4.2. Cancer
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Type
12.7.1. Pirfenidone
12.7.2. Galunisertib
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Transforming Growth Factor Beta 1 Demand Share, 2019-2026
13. Middle East & Africa Transforming Growth Factor Beta 1 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Application
13.4.1. IPF
13.4.2. Cancer
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Transforming Growth Factor Beta 1 Market Size and Volume Forecast by Type
13.7.1. Pirfenidone
13.7.2. Galunisertib
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Transforming Growth Factor Beta 1 Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Transforming Growth Factor Beta 1 Market: Market Share Analysis
14.2. Transforming Growth Factor Beta 1 Distributors and Customers
14.3. Transforming Growth Factor Beta 1 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Shionogi Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Acceleron Pharma Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Genzyme Corp
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Isarna Therapeutics GmbH
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Scholar Rock
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sirnaomics Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eli Lilly and Co
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Formation Biologics Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Novartis AG
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
